Hybrid/Chimera Drugs - Part 1 - Drug Hybrids Affecting Diseases of the Central Nervous System

References

1. NudelmanA. Dimeric drugs.Curr. Med. Chem.202229162751284510.2174/092986732866621081012415934375175
   [Google Scholar]
2. WermuthC.G. GanellinC.R. LindbergP. MitscherL.A. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998).Pure Appl. Chem.19987051129114310.1351/pac199870051129
   [Google Scholar]
3. NudelmanA. Mutual prodrugs or codrugs.Curr. Med. Chem.202330384283433910.2174/092986733066622120910265036503392
   [Google Scholar]
4. AwaltJ.K. NguyenA.T.N. FyfeT.J. ThaiB.S. WhiteP.J. ChristopoulosA. JörgM. MayL.T. ScammellsP.J. Examining the role of the linker in bitopic N-6-substituted adenosine derivatives acting as biased adenosine A1 receptor agonists.J. Med. Chem.202265139076909510.1021/acs.jmedchem.2c0032035729775
   [Google Scholar]
5. KohlstaedtE. KlinglerK.H.U.S. Basic substituted - an) 7-a-kyl. xanthanes or sats thereof. U.S.Patent 3,029,239, 1962.
6. Pubchem, Fenetylline.Available from: https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8315(accessed on 27-5-2024)
7. Wikipedia, Fenethylline.Available from:https://en.wikipedia.org/wiki/Fenethylline(accessed on 27-5-2024)
8. JonesG.B. HuberR.S. MathewsJ.E. LiA. Target directed enediyne prodrugs: Cytotoxic estrogen conjugates.Tetrahedron Lett.199637213643364610.1016/0040‑4039(96)00662‑4
   [Google Scholar]
9. BozorovK. ZhaoJ. AisaH.A. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.Bioorg. Med. Chem.201927163511353110.1016/j.bmc.2019.07.00531300317
   [Google Scholar]
10. XuZ. ZhaoS.J. LiuY. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.Eur. J. Med. Chem.201918311170010.1016/j.ejmech.2019.11170031546197
    [Google Scholar]
11. KumarS.H.M. HerrmannL. TsogoevaS.B. Structural hybridization as a facile approach to new drug candidates.Bioorg. Med. Chem. Lett.2020302312751410.1016/j.bmcl.2020.12751432860980
    [Google Scholar]
12. ShavetaM. MishraS. SinghP. Hybrid molecules: The privileged scaffolds for various pharmaceuticals.Eur. J. Med. Chem.201612450053610.1016/j.ejmech.2016.08.03927598238
    [Google Scholar]
13. AcevedoC.H. ScottiL. AlvesM.F. DinizM.F.F.M. ScottiM.T. Hybrid compounds in the search for alternative chemotherapeutic agents against neglected tropical diseases.Lett. Org. Chem.201916819210.2174/1570178615666180402123057
    [Google Scholar]
14. Henriquez-FiguereoA. Morán-SerradillaC. Angulo-ElizariE. SanmartínC. PlanoD. Small molecules containing chalcogen elements (S, Se, Te) as new warhead to fight neglected tropical diseases.Eur. J. Med. Chem.202324611500210.1016/j.ejmech.2022.11500236493616
    [Google Scholar]
15. Müller-SchiffmannA. StichtH. KorthC. Hybrid Compounds.BioDrugs2012261213110.2165/11597630‑000000000‑0000022239618
    [Google Scholar]
16. ZhaoX. LiuZ. LiuH. GuoJ. LongS. Hybrid molecules based on caffeic acid as potential therapeutics: A focused review.Eur. J. Med. Chem.202224311474510.1016/j.ejmech.2022.11474536152388
    [Google Scholar]
17. AL ZahraniN.A. El-ShishtawyR.M. AsiriA.M. Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review.Eur. J. Med. Chem.202020411260910.1016/j.ejmech.2020.11260932731188
    [Google Scholar]
18. FantacuzziM. AmorosoR. CarradoriS. De FilippisB. Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.Eur. J. Med. Chem.202223311424210.1016/j.ejmech.2022.11424235276424
    [Google Scholar]
19. AlizadehS.R. EbrahimzadehM.A. Quercetin derivatives: Drug design, development, and biological activities, a review.Eur. J. Med. Chem.202222911406810.1016/j.ejmech.2021.11406834971873
    [Google Scholar]
20. SinghK. KumarP. BhatiaR. MehtaV. KumarB. AkhtarM.J. Nipecotic acid as potential lead molecule for the development of GABA uptake inhibitors; structural insights and design strategies.Eur. J. Med. Chem.202223411426910.1016/j.ejmech.2022.11426935306287
    [Google Scholar]
21. HavrylyukD. RomanO. LesykR. Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline–thiazolidine-based hybrids.Eur. J. Med. Chem.201611314516610.1016/j.ejmech.2016.02.03026922234
    [Google Scholar]
22. DuvauchelleV. MeffreP. BenfoddaZ. Recent contribution of medicinally active 2-aminothiophenes: A privileged scaffold for drug discovery.Eur. J. Med. Chem.202223811450210.1016/j.ejmech.2022.11450235696863
    [Google Scholar]
23. VandekerckhoveS. D’hoogheM. Exploration of aziridine- and β-lactam-based hybrids as both bioactive substances and synthetic intermediates in medicinal chemistry.Bioorg. Med. Chem.201321133643364710.1016/j.bmc.2013.04.03323684232
    [Google Scholar]
24. NoureddinS.A. El-ShishtawyR.M. Al-FootyK.O. Curcumin analogues and their hybrid molecules as multifunctional drugs.Eur. J. Med. Chem.201918211163110.1016/j.ejmech.2019.11163131479974
    [Google Scholar]
25. WangJ. GongF. LiangT. XieZ. YangY. CaoC. GaoJ. LuT. ChenX. A review of synthetic bioactive tetrahydro-β-carbolines: A medicinal chemistry perspective.Eur. J. Med. Chem.202122511381510.1016/j.ejmech.2021.11381534479038
    [Google Scholar]
26. SinglaP. SalunkeD.B. Recent advances in steroid amino acid conjugates: Old scaffolds with new dimensions.Eur. J. Med. Chem.202018711190910.1016/j.ejmech.2019.11190931830636
    [Google Scholar]
27. BrandãoP. MarquesC. BurkeA.J. PineiroM. The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules.Eur. J. Med. Chem.202121111310210.1016/j.ejmech.2020.11310233421712
    [Google Scholar]
28. KaminskyyD. KryshchyshynA. LesykR. 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry.Eur. J. Med. Chem.201714054259410.1016/j.ejmech.2017.09.03128987611
    [Google Scholar]
29. GabaS. SainiA. SinghG. MongaV. An insight into the medicinal attributes of berberine derivatives: A review.Bioorg. Med. Chem.20213811614310.1016/j.bmc.2021.11614333848698
    [Google Scholar]
30. ApaydınS. TörökM. Sulfonamide derivatives as multi-target agents for complex diseases.Bioorg. Med. Chem. Lett.201929162042205010.1016/j.bmcl.2019.06.04131272793
    [Google Scholar]
31. VenepallyV. Reddy JalaR.C. An insight into the biological activities of heterocyclic–fatty acid hybrid molecules.Eur. J. Med. Chem.201714111313710.1016/j.ejmech.2017.09.06929031060
    [Google Scholar]
32. ChoudharyS. SinghP.K. VermaH. SinghH. SilakariO. Success stories of natural product-based hybrid molecules for multi-factorial diseases.Eur. J. Med. Chem.2018151629710.1016/j.ejmech.2018.03.05729605809
    [Google Scholar]
33. AutiP.S. GeorgeG. PaulA.T. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids.RSC Advances20201068413534139210.1039/D0RA06642G35516563
    [Google Scholar]
34. GongQ. HuJ. WangP. LiX. ZhangX. A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.Eur. J. Med. Chem.202121011296210.1016/j.ejmech.2020.11296233158575
    [Google Scholar]
35. ZhangX. HeX. ChenQ. LuJ. RapposelliS. PiR. A review on the hybrids of hydroxycinnamic acid as multi-target-directed ligands against Alzheimer’s disease.Bioorg. Med. Chem.201826354355010.1016/j.bmc.2017.12.04229310862
    [Google Scholar]
36. BlaikieL. KayG. Kong LinT.P. Current and emerging therapeutic targets of alzheimer’s disease for the design of multi-target directed ligands.MedChemComm201910122052207210.1039/C9MD00337A32206241
    [Google Scholar]
37. MishraP. KumarA. PandaG. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018).Bioorg. Med. Chem.201927689593010.1016/j.bmc.2019.01.02530744931
    [Google Scholar]
38. SavelieffM.G. NamG. KangJ. LeeH.J. LeeM. LimM.H. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade.Chem. Rev.201911921221132210.1021/acs.chemrev.8b0013830095897
    [Google Scholar]
39. WangL. KumarR. PavlovP.F. WinbladB. Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance.Eur. J. Med. Chem.202120911291510.1016/j.ejmech.2020.11291533139110
    [Google Scholar]
40. SinghY.P. RaiH. SinghG. SinghG.K. MishraS. KumarS. SrikrishnaS. ModiG. A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease.Eur. J. Med. Chem.202121511327810.1016/j.ejmech.2021.11327833662757
    [Google Scholar]
41. HaghighijooZ. ZamaniL. MoosaviF. EmamiS. Therapeutic potential of quinazoline derivatives for Alzheimer’s disease: A comprehensive review.Eur. J. Med. Chem.202222711394910.1016/j.ejmech.2021.11394934742016
    [Google Scholar]
42. MalafaiaD. AlbuquerqueH.M.T. SilvaA.M.S. Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.Eur. J. Med. Chem.202121411320910.1016/j.ejmech.2021.11320933548635
    [Google Scholar]
43. FerreiraJ.P.S. AlbuquerqueH.M.T. CardosoS.M. SilvaA.M.S. SilvaV.L.M. Dual-target compounds for Alzheimer’s disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).Eur. J. Med. Chem.202122111349210.1016/j.ejmech.2021.11349233984802
    [Google Scholar]
44. ZhangH. PengY. ZhuoL. WangY. ZengG. WangS. LongL. LiX. WangZ. Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy.Eur. J. Med. Chem.202224211469510.1016/j.ejmech.2022.11469536044812
    [Google Scholar]
45. SangZ. WangK. DongJ. TangL. Alzheimer’s disease: Updated multi-targets therapeutics are in clinical and in progress.Eur. J. Med. Chem.202223811446410.1016/j.ejmech.2022.11446435635955
    [Google Scholar]
46. MolędaZ. ZawadzkaA. CzarnockiZ. MonjasL. HirschA.K.H. BudzianowskiA. MaurinJ.K. “Clicking” fragment leads to novel dual-binding cholinesterase inhibitors.Bioorg. Med. Chem.20214211626910.1016/j.bmc.2021.11626934130217
    [Google Scholar]
47. Le-Nhat-ThuyG. Nguyen ThiN. Pham-TheH. Dang ThiT.A. Nguyen ThiH. Nguyen ThiT.H. Nguyen HoangS. NguyenT.V. Synthesis and biological evaluation of novel quinazoline-triazole hybrid compounds with potential use in Alzheimer’s disease.Bioorg. Med. Chem. Lett.2020301812740410.1016/j.bmcl.2020.12740432717612
    [Google Scholar]
48. KhanI. IbrarA. ZaibS. AhmadS. FurtmannN. HameedS. SimpsonJ. BajorathJ. IqbalJ. Active compounds from a diverse library of triazolothiadiazole and triazolothiadiazine scaffolds: Synthesis, crystal structure determination, cytotoxicity, cholinesterase inhibitory activity, and binding mode analysis.Bioorg. Med. Chem.201422216163617310.1016/j.bmc.2014.08.02625257911
    [Google Scholar]
49. SivakumarS. Ranjith KumarR. AliM.A. ChoonT.S. An atom economic synthesis and AChE inhibitory activity of novel dispiro 7-aryltetrahydro-1H-pyrrolo[1,2-c][1,3]thiazole and 4-aryloctahydroindolizine N-methylpiperidin-4-one hybrid heterocycles.Eur. J. Med. Chem.20136524024810.1016/j.ejmech.2013.04.05023721952
    [Google Scholar]
50. FangL. ChenM. LiuZ. FangX. GouS. ChenL. Ferulic acid–carbazole hybrid compounds: Combination of cholinesterase inhibition, antioxidant and neuroprotection as multifunctional anti-Alzheimer agents.Bioorg. Med. Chem.201624488689310.1016/j.bmc.2016.01.01026795115
    [Google Scholar]
51. GhobadianR. MahdaviM. NadriH. MoradiA. EdrakiN. AkbarzadehT. SharifzadehM. BukhariS.N.A. AminiM. Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities.Eur. J. Med. Chem.2018155496010.1016/j.ejmech.2018.05.03129857276
    [Google Scholar]
52. AlmansourA.I. ArumugamN. KumarR.S. KotreshaD. ManoharT.S. VenketeshS. Design, synthesis and cholinesterase inhibitory activity of novel spiropyrrolidine tethered imidazole heterocyclic hybrids.Bioorg. Med. Chem. Lett.202030212678910.1016/j.bmcl.2019.12678931753696
    [Google Scholar]
53. AslamS. ZaibS. AhmadM. GardinerJ.M. AhmadA. HameedA. FurtmannN. GütschowM. BajorathJ. IqbalJ. Novel structural hybrids of pyrazolobenzothiazines with benzimidazoles as cholinesterase inhibitors.Eur. J. Med. Chem.20147810611710.1016/j.ejmech.2014.03.03524681070
    [Google Scholar]
54. AbdellatifK.R.A. MoawadA. KnausE.E. Synthesis of new 1-(4-methane(amino)sulfonylphenyl)-5-(4-substituted-aminomethylphenyl)-3-trifluoromethyl-1H-pyrazoles: A search for novel nitric oxide donor anti-inflammatory agents.Bioorg. Med. Chem. Lett.201424215015502110.1016/j.bmcl.2014.09.02425304893
    [Google Scholar]
55. GujralS.S. ShakeriA. HejaziL. RaoP.P.N. Design, synthesis and structure-activity relationship studies of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as amyloid aggregation and cholinesterase inhibitors with antioxidant activity.Eur. J. Med. Chem. Rep.2022610007510.1016/j.ejmcr.2022.100075
    [Google Scholar]
56. WichurT. PasiekaA. GodyńJ. PanekD. GóralI. LataczG. Honkisz-OrzechowskaE. BuckiA. SiwekA. Głuch-LutwinM. KnezD. BrazzolottoX. GobecS. KołaczkowskiM. SabateR. MalawskaB. WięckowskaA. Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau.Eur. J. Med. Chem.202122511378310.1016/j.ejmech.2021.11378334461507
    [Google Scholar]
57. BrandãoP. LópezÓ. LeitzbachL. StarkH. Fernández-BolañosJ.G. BurkeA.J. PineiroM. Ugi reaction synthesis of oxindole-lactam hybrids as selective butyrylcholinesterase inhibitors.ACS Med. Chem. Lett.202112111718172510.1021/acsmedchemlett.1c0034434795859
    [Google Scholar]
58. ReilandK.M. EckroatT.J. Selective butyrylcholinesterase inhibition by isatin dimers and 3-indolyl-3-hydroxy-2-oxindole dimers.Bioorg. Med. Chem. Lett.20227712903710.1016/j.bmcl.2022.12903736307033
    [Google Scholar]
59. kiaY. OsmanH. KumarR.S. BasiriA. MurugaiyahV. Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.Bioorg. Med. Chem.20142241318132810.1016/j.bmc.2014.01.00224461561
    [Google Scholar]
60. KiaY. OsmanH. KumarR.S. MurugaiyahV. BasiriA. PerumalS. RazakI.A. Synthesis of new 1-(4-methane(amino)sulfonylphenyl)-5-(4-substituted-aminomethylphenyl)-3-trifluoromethyl-1H-pyrazoles: A search for novel nitric oxide donor anti-inflammatory agents.Bioorg. Med. Chem. Lett.2013232979298310.1016/j.bmcl.2013.03.02723570788
    [Google Scholar]
61. BuemiM.R. De LucaL. ChimirriA. FerroS. GittoR. Alvarez-BuillaJ. AlajarinR. Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: Synthesis, biological evaluation, and molecular modeling studies.Bioorg. Med. Chem.201321154575458010.1016/j.bmc.2013.05.04423777828
    [Google Scholar]
62. AhmedaH.H. ElmegeedG.A. HashashbM.A. Abd-ElhalimaM.M. El-kadyD.S. Highlights on mechanisms of newly synthesized compounds targeting multiple systems provide a novel perspective on Alzheimer’s disease treatment.J. Chem. Pharm. Res.20157297318
    [Google Scholar]
63. RosiniM. SimoniE. BartoliniM. CavalliA. CeccariniL. PascuN. McClymontD.W. TarozziA. BolognesiM.L. MinariniA. TumiattiV. AndrisanoV. MellorI.R. MelchiorreC. Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer’s disease: a promising direction for the multi-target-directed ligands gold rush.J. Med. Chem.200851154381438410.1021/jm800577j18605718
    [Google Scholar]
64. ReggianiA.M. SimoniE. CaporasoR. MeunierJ. KellerE. MauriceT. MinariniA. RosiniM. CavalliA. In vivo characterization of ARN14140, a memantine/galantamine-based multi-target compound for Alzheimer’s disease.Sci. Rep.2016613317210.1038/srep3317227609215
    [Google Scholar]
65. CaoZ. YangJ. XuR. SongQ. ZhangX. LiuH. QiangX. LiY. TanZ. DengY. Design, synthesis and evaluation of 4′-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment.Bioorg. Med. Chem.20182651102111510.1016/j.bmc.2018.01.03029409707
    [Google Scholar]
66. YangZ. SongQ. CaoZ. YuG. LiuZ. TanZ. DengY. Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer’s disease.Bioorg. Med. Chem.202028711537410.1016/j.bmc.2020.11537432089390
    [Google Scholar]
67. PratiF. BartoliniM. SimoniE. De SimoneA. PintoA. AndrisanoV. BolognesiM.L. Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer’s disease.Bioorg. Med. Chem. Lett.201323236254625810.1016/j.bmcl.2013.09.09124140444
    [Google Scholar]
68. TeixeiraD.R.T. Mimetics of donepezil as potential hybrid drugs against Alzheimer’s disease – synthesis and biochemical evaluation.Master's thesis, University of Lisbon Repository, 2017.
    [Google Scholar]
69. Bhawna KumarA. BhatiaM. KapoorA. KumarP. KumarS. Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies.Eur. J. Med. Chem.202224211465510.1016/j.ejmech.2022.11465536037788
    [Google Scholar]
70. PiemonteseL. TomásD. HiremathadA. CapriatiV. CandeiasE. CardosoS.M. ChavesS. SantosM.A. Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer’s drug candidates.J. Enzyme Inhib. Med. Chem.20183311212122410.1080/14756366.2018.149156430160188
    [Google Scholar]
71. DuH. LiuX. XieJ. MaF. Novel deoxyvasicinone-donepezil hybrids as potential multitarget drug candidates for Alzheimer’s disease.ACS Chem. Neurosci.20191052397240710.1021/acschemneuro.8b0069930720268
    [Google Scholar]
72. BowrojuS.K. PenthalaN.R. LakkanigaN.R. BalasubramaniamM. AyyadevaraS. Shmookler ReisR.J. CrooksP.A. Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease.Bioorg. Med. Chem.20214511631110.1016/j.bmc.2021.11631134304133
    [Google Scholar]
73. NerellaA. JeripothulaM. Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer’s disease.Bioorg. Med. Chem. Lett.20214912821210.1016/j.bmcl.2021.12821234153471
    [Google Scholar]
74. RizzoS. BartoliniM. CeccariniL. PiazziL. GobbiS. CavalliA. RecanatiniM. AndrisanoV. RampaA. Targeting Alzheimer’s disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.Bioorg. Med. Chem.20101851749176010.1016/j.bmc.2010.01.07120171894
    [Google Scholar]
75. ValenciaE.M. Herrera-ArozamenaC. de AndrésL. PérezC. Morales-GarcíaJ.A. Pérez-CastilloA. RamosE. RomeroA. ViñaD. YáñezM. LauriniE. PriclS. Rodríguez-FrancoM.I. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer’s disease.Eur. J. Med. Chem.201815653455310.1016/j.ejmech.2018.07.026
    [Google Scholar]
76. DiasK.S.T. de PaulaC.T. dos SantosT. SouzaI.N.O. BoniM.S. GuimarãesM.J.R. da SilvaF.M.R. CastroN.G. NevesG.A. VelosoC.C. CoelhoM.M. de MeloI.S.F. GiustiF.C.V. Giusti-PaivaA. da SilvaM.L. DardenneL.E. GuedesI.A. PruccoliL. MorroniF. TarozziA. ViegasC.Jr Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.201713044045710.1016/j.ejmech.2017.02.043
    [Google Scholar]
77. SangZ. WangK. WangH. WangH. MaQ. HanX. YeM. YuL. LiuW. Design, synthesis and biological evaluation of 2-acetyl-5- O -(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.201727225046505210.1016/j.bmcl.2017.09.05729033233
    [Google Scholar]
78. PanW. HuK. BaiP. YuL. MaQ. LiT. ZhangX. ChenC. PengK. LiuW. SangZ. Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.201626102539254310.1016/j.bmcl.2016.03.08627072909
    [Google Scholar]
79. BrunettiL. LeuciR. CarrieriA. CattoM. OcchineriS. VinciG. GambacortaL. BaltrukevichH. ChavesS. LaghezzaA. AltomareC.D. TortorellaP.M. Amélia, S.; Fulvio, L.; Luca, P. Structure-based design of novel donepezil-like hybrids for a multitarget approach to the therapy of Alzheimer’s disease.Eur. J. Med. Chem.202223711435810.1016/j.ejmech.2022.11435835462163
    [Google Scholar]
80. CampsP. FormosaX. GaldeanoC. GómezT. Muñoz-TorreroD. ScarpelliniM. ViaynaE. BadiaA. ClosM.V. CaminsA. PallàsM. BartoliniM. ManciniF. AndrisanoV. EstelrichJ. LizondoM. Bidon-ChanalA. LuqueF.J. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation.J. Med. Chem.200851123588359810.1021/jm800131318517184
    [Google Scholar]
81. SangZ. BaiP. BanY. WangK. WuA. MiJ. HuJ. XuR. ZhuG. WangJ. ZhangJ. WangC. TanZ. TangL. Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer’s agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies.Bioorg. Chem.202212710600710.1016/j.bioorg.2022.10600735849893
    [Google Scholar]
82. FangL. ShenS. LiuQ. LiuZ. ZhaoJ. Combination of NSAIDs with donepezil as multi-target directed ligands for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.20227512897610.1016/j.bmcl.2022.12897636067929
    [Google Scholar]
83. AlonsoD. DorronsoroI. RubioL. MuñozP. García-PalomeroE. Del MonteM. Bidon-ChanalA. OrozcoM. LuqueF.J. CastroA. MedinaM. MartínezA. Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChE.Bioorg. Med. Chem.200513246588659710.1016/j.bmc.2005.09.02916230018
    [Google Scholar]
84. WangJ. WangZ.M. LiX.M. LiF. WuJ.J. KongL.Y. WangX.B. Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer’s disease based on the fusion of donepezil and melatonin.Bioorg. Med. Chem.201624184324433810.1016/j.bmc.2016.07.02527460699
    [Google Scholar]
85. GabrM.T. Abdel-RaziqM.S. Structure-based design, synthesis, and evaluation of structurally rigid donepezil analogues as dual AChE and BACE-1 inhibitors.Bioorg. Med. Chem. Lett.201828172910291310.1016/j.bmcl.2018.07.01930017317
    [Google Scholar]
86. MatosM.J. ViñaD. QuezadaE. PicciauC. DeloguG. OralloF. SantanaL. UriarteE. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.Bioorg. Med. Chem. Lett.200919123268327010.1016/j.bmcl.2009.04.08519423346
    [Google Scholar]
87. MatosM.J. ViñaD. JaneiroP. BorgesF. SantanaL. UriarteE. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.Bioorg. Med. Chem. Lett.201020175157516010.1016/j.bmcl.2010.07.01320659799
    [Google Scholar]
88. MatosM.J. ViñaD. PicciauC. OralloF. SantanaL. UriarteE. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.Bioorg. Med. Chem. Lett.200919175053505510.1016/j.bmcl.2009.07.03919628387
    [Google Scholar]
89. XieS.S. LiuJ. TangC. PangC. LiQ. QinY. NongX. ZhangZ. GuoJ. ChengM. TangW. LiangN. JiangN. Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-β and amyloid-β aggregation against Alzheimer’s disease.Eur. J. Med. Chem.202020211247510.1016/j.ejmech.2020.11247532652406
    [Google Scholar]
90. JiangX. GuoJ. LvY. YaoC. ZhangC. MiZ. ShiY. GuJ. ZhouT. BaiR. XieY. Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.Bioorg. Med. Chem.2020281211555010.1016/j.bmc.2020.11555032503694
    [Google Scholar]
91. YangH.L. CaiP. LiuQ.H. YangX.L. LiF. WangJ. WuJ.J. WangX.B. KongL.Y. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid- β aggregation for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.201713871572810.1016/j.ejmech.2017.07.00828728104
    [Google Scholar]
92. XieS.S. LanJ.S. WangX. WangZ.M. JiangN. LiF. WuJ.J. WangJ. KongL.Y. Design, synthesis and biological evaluation of novel donepezil–coumarin hybrids as multi-target agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.20162471528153910.1016/j.bmc.2016.02.02326917219
    [Google Scholar]
93. HuangM. XieS.S. JiangN. LanJ.S. KongL.Y. WangX.B. Multifunctional coumarin derivatives: Monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer’s disease.Bioorg. Med. Chem. Lett.201525350851310.1016/j.bmcl.2014.12.03425542589
    [Google Scholar]
94. ZhangC. YangK. YuS. SuJ. YuanS. HanJ. ChenY. GuJ. ZhouT. BaiR. XieY. Synthesis and evaluation of hydroxypyridinonecoumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer’s disease.Eur. J. Med. Chem.201918036738210.1016/j.ejmech.2019.07.03131325784
    [Google Scholar]
95. GirekM. SzymańskiP. Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities.Chem. Pap.201973226928910.1007/s11696‑018‑0590‑8
    [Google Scholar]
96. GirekM. SzymańskiP. Phyto-tacrine hybrids as promising drugs to treat Alzheimer’s disease.ChemistrySelect20194195776579010.1002/slct.201803672
    [Google Scholar]
97. RomeroA. CacabelosR. Oset-GasqueM.J. SamadiA. Marco-ContellesJ. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.20132371916192210.1016/j.bmcl.2013.02.01723481643
    [Google Scholar]
98. SpilovskaK. KorabecnyJ. NepovimovaE. DolezalR. MezeiovaE. SoukupO. KucaK. Multitarget tacrine hybrids with neuroprotective properties to confront Alzheimer’s disease.Curr. Top. Med. Chem.20171791006102610.2174/156802660566616092715272827697055
    [Google Scholar]
99. SameemB. SaeediM. MahdaviM. ShafieeA. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer’s disease.Eur. J. Med. Chem.201712833234510.1016/j.ejmech.2016.10.06027876467
    [Google Scholar]
100. Oset-GasqueM.J. Marco-ContellesJ.L. Tacrine-natural-product hybrids for Alzheimer’s disease therapy.Curr. Med. Chem.202027264392440010.2174/092986732566618040315172529611473
     [Google Scholar]
101. HamulakovaS. KudlickovaZ. JanovecL. MezencevR. DecknerZ.J. ChernoffY.O. JanockovaJ. IhnatovaV. BzonekP. NovakovaN. HepnarovaV. HrabinovaM. JunD. KorabecnyJ. SoukupO. KucaK. Design and synthesis of novel tacrine-indole hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease.Future Med. Chem.202113978580410.4155/fmc‑2020‑018433829876
     [Google Scholar]
102. BornsteinJ.J. EckroatT.J. HoughtonJ.L. JonesC.K. GreenK.D. Garneau-TsodikovaS. Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase.MedChemComm20112540641210.1039/c0md00256a
     [Google Scholar]
103. ChenY. SunJ. HuangZ. LiaoH. PengS. LehmannJ. ZhangY. Design, synthesis and evaluation of tacrine–flurbiprofen–nitrate trihybrids as novel anti-Alzheimer’s disease agents.Bioorg. Med. Chem.20132192462247010.1016/j.bmc.2013.03.00523541836
     [Google Scholar]
104. ChenY. SunJ. PengS. LiaoH. ZhangY. LehmannJ. Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer’s disease.Arch. Pharm. (Weinheim)20133461286587110.1002/ardp.20130007424203864
     [Google Scholar]
105. LiuZ. ZhangB. XiaS. FangL. GouS. ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker.Eur. J. Med. Chem.202121211299710.1016/j.ejmech.2020.11299733189440
     [Google Scholar]
106. ChiouaM. BuzziE. MoraledaI. IriepaI. MajM. WnorowskiA. GiovanniniC. TramarinA. PortaliF. IsmailiL. López-AlvaradoP. BolognesiM.L. JóźwiakK. MenéndezJ.C. Marco-ContellesJ. BartoliniM. Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer’s disease.Eur. J. Med. Chem.201815583984610.1016/j.ejmech.2018.06.04429958119
     [Google Scholar]
107. LeónR. RíosC. Marco-ContellesJ. HuertasO. BarrilX. Javier LuqueF. LópezM.G. GarcíaA.G. VillarroyaM. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties.Bioorg. Med. Chem.200816167759776910.1016/j.bmc.2008.07.00518640842
     [Google Scholar]
108. WangY. WangF. YuJ.P. JiangF.C. GuanX.L. WangC.M. LiL. CaoH. LiM.X. ChenJ.G. Novel multipotent phenylthiazole–tacrine hybrids for the inhibition of cholinesterase activity, β-amyloid aggregation and Ca2+ overload.Bioorg. Med. Chem.201220216513652210.1016/j.bmc.2012.08.04023000296
     [Google Scholar]
109. JiangX.Y. ChenT.K. ZhouJ.T. HeS.Y. YangH.Y. ChenY. QuW. FengF. SunH.P. Dual GSK-3β/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer’s disease drug discovery.ACS Med. Chem. Lett.20189317117610.1021/acsmedchemlett.7b0046329541355
     [Google Scholar]
110. LiuW. LiuX. LiuW. GaoY. WuL. HuangY. ChenH. LiD. ZhouL. WangN. XuZ. JiangX. ZhaoQ. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.202222911409510.1016/j.ejmech.2021.11409534995924
     [Google Scholar]
111. JeřábekJ. UliassiE. GuidottiL. KorábečnýJ. SoukupO. SepsovaV. HrabinovaM. KučaK. BartoliniM. Peña-AltamiraL.E. PetrallaS. MontiB. RobertiM. BolognesiM.L. Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer’s disease.Eur. J. Med. Chem.201712725026210.1016/j.ejmech.2016.12.04828064079
     [Google Scholar]
112. ViaynaE. GómezT. GaldeanoC. RamírezL. RatiaM. BadiaA. ClosM.V. VerdaguerE. JunyentF. CaminsA. PallàsM. BartoliniM. ManciniF. AndrisanoV. ArceM.P. Rodríguez-FrancoM.I. Bidon-ChanalA. LuqueF.J. CampsP. Muñoz-TorreroD. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates.ChemMedChem20105111855187010.1002/cmdc.20100032220859987
     [Google Scholar]
113. GaldeanoC. ViaynaE. SolaI. FormosaX. CampsP. BadiaA. ClosM.V. RelatJ. RatiaM. BartoliniM. ManciniF. AndrisanoV. SalmonaM. MinguillónC. González-MuñozG.C. Rodríguez-FrancoM.I. Bidon-ChanalA. LuqueF.J. Muñoz-TorreroD. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer’s and prion diseases.J. Med. Chem.201255266166910.1021/jm200840c22185619
     [Google Scholar]
114. MezeiovaE. HrabinovaM. HepnarovaV. JunD. JanockovaJ. MuckovaL. PrchalL. KristofikovaZ. KuceraT. GoreckiL. ChalupovaK. KunesJ. HroudovaJ. SoukupO. KorabecnyJ. HuprineY. Tryptophan heterodimers with potential implication to Alzheimer’s disease treatment.Bioorg. Med. Chem. Lett.20214312810010.1016/j.bmcl.2021.12810033984470
     [Google Scholar]
115. CeschiM.A. Sobieski da CostaJ. DardenneL.E. Synthesis and activity towards Alzheimer’s disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.Eur. J. Med. Chem.201612175877210.1016/j.ejmech.2016.06.02527392529
     [Google Scholar]
116. LiG. HongG. LiX. ZhangY. XuZ. MaoL. FengX. LiuT. Synthesis and activity towards Alzheimer’s disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.Eur. J. Med. Chem.201814823825410.1016/j.ejmech.2018.01.02829466774
     [Google Scholar]
117. LinR. RaoS. LiY. ZhangL. XuL. HeY. LiuZ. ChenH. Conjugation of tacrine with genipin derivative not only enhances effects on AChE but also leads to autophagy against Alzheimer’s disease.Eur. J. Med. Chem.202121111306710.1016/j.ejmech.2020.11306733338868
     [Google Scholar]
118. KálaiT. AltmanR. MaezawaI. BalogM. MorisseauC. PetrlovaJ. HammockB.D. JinL.W. TrudellJ.R. VossJ.C. HidegK. Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors.Eur. J. Med. Chem.20147734335010.1016/j.ejmech.2014.03.02624657571
     [Google Scholar]
119. FangL. AppenrothD. DeckerM. KiehntopfM. RoeglerC. DeufelT. FleckC. PengS. ZhangY. LehmannJ. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.J. Med. Chem.200851471371610.1021/jm701491k18232655
     [Google Scholar]
120. CeschiM. PilottiR. LopesJ. DapontH. da RochaJ. AfolabiB. GuedesI. DardenneL. An Expedient Synthesis of Tacrine-Squaric Hybrids as Potent, Selective and Dual‑Binding Cholinesterase Inhibitors.J. Braz. Chem. Soc.20203185786610.21577/0103‑5053.20200019
     [Google Scholar]
121. LopesJ.P.B. SilvaL. da Costa FranarinG. Antonio CeschiM. Seibert LüdtkeD. Ferreira DantasR. de SallesC.M.C. Paes Silva-JrF. Roberto SengerM. Alvim GuedesI. Emmanuel DardenneL. Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives.Bioorg. Med. Chem.201826205566557710.1016/j.bmc.2018.10.00330340901
     [Google Scholar]
122. ScipioniM. KayG. MegsonI.L. Kong Thoo LinP. Synthesis of novel vanillin derivatives: novel multi-targeted scaffold ligands against Alzheimer’s disease.MedChemComm201910576477710.1039/C9MD00048H31191867
     [Google Scholar]
123. FangL. KrausB. LehmannJ. HeilmannJ. ZhangY. DeckerM. Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.Bioorg. Med. Chem. Lett.20081892905290910.1016/j.bmcl.2008.03.07318406135
     [Google Scholar]
124. FuY. MuY. LeiH. WangP. LiX. LengQ. HanL. QuX. WangZ. HuangX. Design, synthesis, and evaluation of novel tacrine-ferulic acid hybrids as multifunctional drug candidates against Alzheimer’s Disease.Molecules20162111010.3390/molecules21101338
     [Google Scholar]
125. ChaoX. HeX. YangY. ZhouX. JinM. LiuS. ChengZ. LiuP. WangY. YuJ. TanY. HuangY. QinJ. RapposelliS. PiR. Design, synthesis and pharmacological evaluation of novel tacrine–caffeic acid hybrids as multi-targeted compounds against Alzheimer’s disease.Bioorg. Med. Chem. Lett.201222206498650210.1016/j.bmcl.2012.08.03622981331
     [Google Scholar]
126. DigiacomoM. ChenZ. WangS. LapucciA. MacchiaM. YangX. ChuJ. HanY. PiR. RapposelliS. Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD.Bioorg. Med. Chem. Lett.201525480781010.1016/j.bmcl.2014.12.08425597007
     [Google Scholar]
127. XieS.S. LanJ.S. WangX.B. JiangN. DongG. LiZ.R. WangK.D.G. GuoP.P. KongL.Y. Multifunctional tacrine–trolox hybrids for the treatment of Alzheimer’s disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.Eur. J. Med. Chem.201593425010.1016/j.ejmech.2015.01.05825656088
     [Google Scholar]
128. LanJ.S. XieS.S. LiS.Y. PanL.F. WangX.B. KongL.Y. Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.201422216089610410.1016/j.bmc.2014.08.03525282654
     [Google Scholar]
129. LiS.Y. WangX.B. XieS.S. JiangN. WangK.D.G. YaoH.Q. SunH.B. KongL.Y. Multifunctional tacrine–flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.20136963264610.1016/j.ejmech.2013.09.02424095756
     [Google Scholar]
130. CenJ. GuoH. HongC. LvJ. YangY. WangT. FangD. LuoW. WangC. Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity.Eur. J. Med. Chem.201814412813610.1016/j.ejmech.2017.12.00529268129
     [Google Scholar]
131. KochiA. EckroatT.J. GreenK.D. MayhoubA.S. LimM.H. Garneau-TsodikovaS. A novel hybrid of 6-chlorotacrine and metal–amyloid-β modulator for inhibition of acetylcholinesterase and metal-induced amyloid-β aggregation.Chem. Sci. (Camb.)20134114137414510.1039/c3sc51902c
     [Google Scholar]
132. EckroatT.J. GreenK.D. ReedR.A. BornsteinJ.J. Garneau-TsodikovaS. Investigation of the role of linker moieties in bifunctional tacrine hybrids.Bioorg. Med. Chem.201321123614362310.1016/j.bmc.2013.02.04723535563
     [Google Scholar]
133. LiuZ. FangL. ZhangH. GouS. ChenL. Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property.Bioorg. Med. Chem.20172582387239810.1016/j.bmc.2017.02.04928302511
     [Google Scholar]
134. De LorenziE. SeghettiF. TarozziA. PruccoliL. ContardiC. SerraM. BisiA. GobbiS. VistoliG. GervasoniS. ArgentiniC. GhirardoG. GuaratoG. OrsoG. BellutiF. Di MartinoR.M.C. ZussoM. Targeting the multifaceted neurotoxicity of Alzheimer’s disease by tailored functionalisation of the curcumin scaffold.Eur. J. Med. Chem.202325211529710.1016/j.ejmech.2023.11529736996713
     [Google Scholar]
135. KeriR.S. QuintanovaC. ChavesS. SilvaD.F. CardosoS.M. SantosM.A. New Tacrine Hybrids with Natural‐Based Cysteine Derivatives as Multitargeted Drugs for Potential Treatment of Alzheimer’s Disease.Chem. Biol. Drug Des.201687110111110.1111/cbdd.1263326256122
     [Google Scholar]
136. LuC. ZhouQ. YanJ. DuZ. HuangL. LiX. A novel series of tacrine–selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.20136274575310.1016/j.ejmech.2013.01.03923454517
     [Google Scholar]
137. TeponnouG.A.K. JoubertJ. MalanS.F. Tacrine, Trolox and Tryptoline as Lead Compounds for the Design and Synthesis of Multi-target Agents for Alzheimer’s Disease Therapy.Open Med. Chem. J.2017111243710.2174/187410450171101002428567126
     [Google Scholar]
138. do Carmo CarreirasM. IsmailiL. Marco-ContellesJ. Propargylamine-derived multi-target directed ligands for Alzheimer’s disease therapy.Bioorg. Med. Chem. Lett.202030312688010.1016/j.bmcl.2019.12688031864798
     [Google Scholar]
139. Rodríguez-FrancoM.I. Fernández-BachillerM.I. PérezC. Hernández-LedesmaB. BartoloméB. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.J. Med. Chem.200649245946210.1021/jm050746d16420031
     [Google Scholar]
140. MaoF. ChenJ. ZhouQ. LuoZ. HuangL. LiX. Novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.Bioorg. Med. Chem. Lett.201323246737674210.1016/j.bmcl.2013.10.03424220172
     [Google Scholar]
141. ChufarovaN. CzarneckaK. SkibińskiR. CuchraM. MajsterekI. SzymańskiP. New tacrine–acridine hybrids as promising multifunctional drugs for potential treatment of Alzheimer’s disease.Arch. Pharm. (Weinheim)20183517180005010.1002/ardp.20180005029870588
     [Google Scholar]
142. FancelluG. ChandK. TomásD. OrlandiniE. PiemonteseL. SilvaD.F. CardosoS.M. ChavesS. SantosM.A. Novel tacrine–benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer’s Disease.J. Enzyme Inhib. Med. Chem.202035121122610.1080/14756366.2019.168923731760822
     [Google Scholar]
143. XieS.S. WangX. JiangN. YuW. WangK.D.G. LanJ.S. LiZ.R. KongL.Y. Multi-target tacrine-coumarin hybrids: Cholinesterase and monoamine oxidase B inhibition properties against Alzheimer’s disease.Eur. J. Med. Chem.20159515316510.1016/j.ejmech.2015.03.04025812965
     [Google Scholar]
144. SunQ. PengD.Y. YangS.G. ZhuX.L. YangW.C. YangG.F. Syntheses of coumarin–tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.Bioorg. Med. Chem.201422174784479110.1016/j.bmc.2014.06.05725088549
     [Google Scholar]
145. XieS.S. WangX.B. LiJ.Y. YangL. KongL.Y. Design, synthesis and evaluation of novel tacrine–coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer’s disease.Eur. J. Med. Chem.20136454055310.1016/j.ejmech.2013.03.05123685572
     [Google Scholar]
146. Fernández-BachillerM.I. PérezC. MonjasL. RademannJ. Rodríguez-FrancoM.I. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer’s disease, with cholinergic, antioxidant, and β-amyloid-reducing properties.J. Med. Chem.20125531303131710.1021/jm201460y22243648
     [Google Scholar]
147. LiaoS. DengH. HuangS. YangJ. WangS. YinB. ZhengT. ZhangD. LiuJ. GaoG. MaJ. DengZ. Design, synthesis and evaluation of novel 5,6,7-trimethoxyflavone–6-chlorotacrine hybrids as potential multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.20152571541154510.1016/j.bmcl.2015.02.01525724825
     [Google Scholar]
148. SunY. ChenJ. ChenX. HuangL. LiX. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine–Homoisoflavonoid hybrids.Bioorg. Med. Chem.201321237406741710.1016/j.bmc.2013.09.05024128814
     [Google Scholar]
149. HamulakovaS. PopracP. JomovaK. BrezovaV. LauroP. DrostinovaL. JunD. SepsovaV. HrabinovaM. SoukupO. KristianP. GazovaZ. BednarikovaZ. KucaK. ValkoM. Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer’s disease using multifunctional tacrine-coumarin hybrid molecules.J. Inorg. Biochem.2016161526210.1016/j.jinorgbio.2016.05.00127230386
     [Google Scholar]
150. LuoW. LiY.P. HeY. HuangS.L. TanJ.H. OuT.M. LiD. GuL.Q. HuangZ.S. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation.Bioorg. Med. Chem.201119276377010.1016/j.bmc.2010.12.02221211982
     [Google Scholar]
151. ZhangC. DuQ.Y. ChenL.D. WuW.H. LiaoS.Y. YuL.H. LiangX.T. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as multi-targeted compounds against Alzheimer’s disease.Eur. J. Med. Chem.201611620020910.1016/j.ejmech.2016.03.07727061983
     [Google Scholar]
152. TangH. ZhaoL.Z. ZhaoH.T. HuangS.L. ZhongS.M. QinJ.K. ChenZ.F. HuangZ.S. LiangH. Hybrids of oxoisoaporphine-tacrine congeners: Novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.Eur. J. Med. Chem.201146104970497910.1016/j.ejmech.2011.08.00221871694
     [Google Scholar]
153. TangH. NingF.X. WeiY.B. HuangS.L. HuangZ.S. ChanA.S.C. GuL.Q. Derivatives of oxoisoaporphine alkaloids: A novel class of selective acetylcholinesterase inhibitors.Bioorg. Med. Chem. Lett.200717133765376810.1016/j.bmcl.2007.04.01517451950
     [Google Scholar]
154. WeiS. ChenW. QinJ. HuangliY. WangL. ShenY. TangH. Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer’s disease.Bioorg. Med. Chem.201624226031603910.1016/j.bmc.2016.09.06127720328
     [Google Scholar]
155. IpF.C.F. FuG. YangF. KangF. SunP. LingC.Y. CheungK. XieF. HuY. FuL. IpN.Y. A tacrine-tetrahydroquinoline heterodimer potently inhibits acetylcholinesterase activity and enhances neurotransmission in mice.Eur. J. Med. Chem.202122611382710.1016/j.ejmech.2021.11382734530383
     [Google Scholar]
156. Di PietroO. Pérez-ArealesF.J. Juárez-JiménezJ. EspargaróA. ClosM.V. PérezB. LavillaR. SabatéR. LuqueF.J. Muñoz-TorreroD. Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.Eur. J. Med. Chem.20148410711710.1016/j.ejmech.2014.07.02125016233
     [Google Scholar]
157. HepnarovaV. KorabecnyJ. MatouskovaL. JostP. MuckovaL. HrabinovaM. VykoukalovaN. KerhartovaM. KuceraT. DolezalR. NepovimovaE. SpilovskaK. MezeiovaE. PhamN.L. JunD. StaudF. KapingD. KucaK. SoukupO. The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer’s disease.Eur. J. Med. Chem.201815029230610.1016/j.ejmech.2018.02.08329533874
     [Google Scholar]
158. ShaoD. ZouC. LuoC. TangX. LiY. Synthesis and evaluation of tacrine–E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.200414184639464210.1016/j.bmcl.2004.07.00515324879
     [Google Scholar]
159. MaoF. HuangL. LuoZ. LiuA. LuC. XieZ. LiX. O-Hydroxyl- or o-amino benzylamine-tacrine hybrids: Multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-β aggregation.Bioorg. Med. Chem.201220195884589210.1016/j.bmc.2012.07.04522944335
     [Google Scholar]
160. LangeJ.H.M. CoolenH.K.A.C. van der NeutM.A.W. BorstA.J.M. StorkB. VerveerP.C. KruseC.G. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.J. Med. Chem.20105331338134610.1021/jm901614b20047331
     [Google Scholar]
161. DerabliC. BoualiaI. AbdelwahabA.B. BoulcinaR. BensouiciC. KirschG. DebacheA. A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.Bioorg. Med. Chem. Lett.201828142481248410.1016/j.bmcl.2018.05.06329887354
     [Google Scholar]
162. PanT. XieS. ZhouY. HuJ. LuoH. LiX. HuangL. Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer’s disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.Bioorg. Med. Chem. Lett.201929162150215210.1016/j.bmcl.2019.06.05631281020
     [Google Scholar]
163. NajafiZ. MahdaviM. SaeediM. Karimpour-RazkenariE. AsatouriR. VafadarnejadF. MoghadamF.H. KhanaviM. SharifzadehM. AkbarzadehT. Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors.Eur. J. Med. Chem.20171251200121210.1016/j.ejmech.2016.11.00827863370
     [Google Scholar]
164. HiremathadA. KeriR.S. EstevesA.R. CardosoS.M. ChavesS. SantosM.A. Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer’s disease.Eur. J. Med. Chem.201814825526710.1016/j.ejmech.2018.02.02329466775
     [Google Scholar]
165. HuangL. SuT. ShanW. LuoZ. SunY. HeF. LiX. Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids.Bioorg. Med. Chem.20122093038304810.1016/j.bmc.2012.02.05922472046
     [Google Scholar]
166. KeriR.S. QuintanovaC. MarquesS.M. EstevesA.R. CardosoS.M. SantosM.A. Design, synthesis and neuroprotective evaluation of novel tacrine–benzothiazole hybrids as multi-targeted compounds against Alzheimer’s disease.Bioorg. Med. Chem.201321154559456910.1016/j.bmc.2013.05.02823768661
     [Google Scholar]
167. ThiratmatrakulS. YenjaiC. WaiwutP. VajraguptaO. ReubroycharoenP. TohdaM. BoonyaratC. Synthesis, biological evaluation and molecular modeling study of novel tacrine–carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.201475213010.1016/j.ejmech.2014.01.02024508831
     [Google Scholar]
168. LanJ.S. DingY. LiuY. KangP. HouJ.W. ZhangX.Y. XieS.S. ZhangT. Design, synthesis and biological evaluation of novel coumarin- N -benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.2017139485910.1016/j.ejmech.2017.07.05528797883
     [Google Scholar]
169. JiangN. HuangQ. LiuJ. LiangN. LiQ. LiQ. XieS.S. Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.201814628729810.1016/j.ejmech.2018.01.05529407958
     [Google Scholar]
170. QiangX. LiY. YangX. LuoL. XuR. ZhengY. CaoZ. TanZ. DengY. DL -3- n -butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid- β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer’s therapy.Bioorg. Med. Chem. Lett.201727471872210.1016/j.bmcl.2017.01.05028131710
     [Google Scholar]
171. MacklinL.J. SchwansJ.P. Synthesis, biochemical evaluation, and molecular modeling of organophosphate-coumarin hybrids as potent and selective butyrylcholinesterase inhibitors.Bioorg. Med. Chem. Lett.2020301312721310.1016/j.bmcl.2020.12721332381396
     [Google Scholar]
172. LiuW. WuL. LiuW. TianL. ChenH. WuZ. WangN. LiuX. QiuJ. FengX. XuZ. JiangX. ZhaoQ. Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.202224211468910.1016/j.ejmech.2022.11468936007469
     [Google Scholar]
173. HuangL. LuoZ. HeF. ShiA. QinF. LiX. Berberine derivatives, with substituted amino groups linked at the 9-position, as inhibitors of acetylcholinesterase/butyrylcholinesterase.Bioorg. Med. Chem. Lett.201020226649665210.1016/j.bmcl.2010.09.01320880702
     [Google Scholar]
174. HuangL. ShiA. HeF. LiX. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.Bioorg. Med. Chem.20101831244125110.1016/j.bmc.2009.12.03520056426
     [Google Scholar]
175. JiangH. WangX. HuangL. LuoZ. SuT. DingK. LiX. Benzenediol-berberine hybrids: Multifunctional agents for Alzheimer’s disease.Bioorg. Med. Chem.201119237228723510.1016/j.bmc.2011.09.04022041172
     [Google Scholar]
176. SuT. XieS. WeiH. YanJ. HuangL. LiX. Synthesis and biological evaluation of berberine–thiophenyl hybrids as multi-functional agents: Inhibition of acetylcholinesterase, butyrylcholinesterase, and Aβ aggregation and antioxidant activity.Bioorg. Med. Chem.201321185830584010.1016/j.bmc.2013.07.01123932451
     [Google Scholar]
177. JiangX. ZhangZ. ZuoJ. WuC. ZhaL. XuY. WangS. ShiJ. LiuX.H. ZhangJ. TangW. Novel cannabidiol−carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer’s disease.Eur. J. Med. Chem.202122311373510.1016/j.ejmech.2021.11373534371367
     [Google Scholar]
178. SpatzP. SteinmüllerS.A.M. TutovA. PoetaE. MorilleauA. CarlesA. DeventerM.H. HofmannJ. StoveC.P. MontiB. MauriceT. DeckerM. Dual-acting small molecules: Subtype-selective cannabinoid receptor 2 agonist/butyrylcholinesterase inhibitor hybrids show neuroprotection in an Alzheimer’s disease mouse model.J. Med. Chem.20236696414643510.1021/acs.jmedchem.3c0054137127287
     [Google Scholar]
179. HuangW. TangL. ShiY. HuangS. XuL. ShengR. WuP. LiJ. ZhouN. HuY. Searching for the Multi-Target-Directed Ligands against Alzheimer’s disease: Discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities.Bioorg. Med. Chem.201119237158716710.1016/j.bmc.2011.09.06122019465
     [Google Scholar]
180. ArumugamN. AlmansourA.I. KumarR.S. KotreshaD. SaiswaroopR. VenketeshS. Dispiropyrrolidinyl-piperidone embedded indeno[1,2-b]quinoxaline heterocyclic hybrids: Synthesis, cholinesterase inhibitory activity and their molecular docking simulation.Bioorg. Med. Chem.201927122621262810.1016/j.bmc.2019.03.05830952387
     [Google Scholar]
181. LiY. PengP. TangL. HuY. HuY. ShengR. Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer’s disease therapy.Bioorg. Med. Chem.201422174717472510.1016/j.bmc.2014.07.00925082512
     [Google Scholar]
182. SangZ. LiY. QiangX. XiaoG. LiuQ. TanZ. DengY. Multifunctional scutellarin–rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.201523466868010.1016/j.bmc.2015.01.00525614117
     [Google Scholar]
183. WangL. WangY. TianY. ShangJ. SunX. ChenH. WangH. TanW. Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.Bioorg. Med. Chem.201725136037110.1016/j.bmc.2016.11.00227856236
     [Google Scholar]
184. XiaoG. LiY. QiangX. XuR. ZhengY. CaoZ. LuoL. YangX. SangZ. SuF. DengY. Design, synthesis and biological evaluation of 4′-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease.Bioorg. Med. Chem.20172531030104110.1016/j.bmc.2016.12.01328011206
     [Google Scholar]
185. ChenZ. DigiacomoM. TuY. GuQ. WangS. YangX. ChuJ. ChenQ. HanY. ChenJ. NesiG. SestitoS. MacchiaM. RapposelliS. PiR. Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer’s disease.Eur. J. Med. Chem.201712578479210.1016/j.ejmech.2016.09.05227736684
     [Google Scholar]
186. SangZ. WangK. ShiJ. ChengX. ZhuG. WeiR. MaQ. YuL. ZhaoY. TanZ. LiuW. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.202018711195810.1016/j.ejmech.2019.11195831865014
     [Google Scholar]
187. SestitoS. PruccoliL. RunfolaM. CitiV. MartelliA. SaccomanniG. CalderoneV. TarozziA. RapposelliS. Design and synthesis of H2S-donor hybrids: A new treatment for Alzheimer’s disease?Eur. J. Med. Chem.201918411174510.1016/j.ejmech.2019.11174531585237
     [Google Scholar]
188. XuP. ZhangM. ShengR. MaY. Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ 1–42 aggregation inhibitors and metal-chelating agents for Alzheimer’s disease.Eur. J. Med. Chem.201712717418610.1016/j.ejmech.2016.12.04528061347
     [Google Scholar]
189. ChengG. XuP. ZhangM. ChenJ. ShengR. MaY. Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer’s disease.Bioorg. Med. Chem.201826225759576510.1016/j.bmc.2018.08.01130360953
     [Google Scholar]
190. LiuX. YuC. YaoY. LaiH. YeX. XuJ. GuoJ. XiaoX. LinC. HuangZ. LinJ. YuC. ZhaD. Novel neuroprotective pyromeconic acid derivatives with concurrent anti-Aβ deposition, anti-inflammatory, and anti-oxidation properties for treatment of Alzheimer’s disease.Eur. J. Med. Chem.202324811512010.1016/j.ejmech.2023.11512036682173
     [Google Scholar]
191. GuttiG. LeifeldJ. KakarlaR. BajadN.G. GaneshpurkarA. KumarA. KrishnamurthyS. Klein-SchmidtC. TapkenD. HollmannM. SinghS.K. Discovery of triazole-bridged aryl adamantane analogs as an intriguing class of multifunctional agents for treatment of Alzheimer’s disease.Eur. J. Med. Chem.202325911567010.1016/j.ejmech.2023.11567037515920
     [Google Scholar]
192. KushwahaP. FatimaS. UpadhyayA. GuptaS. BhagwatiS. BaghelT. SiddiqiM.I. NazirA. SashidharaK.V. Synthesis, biological evaluation and molecular dynamic simulations of novel Benzofuran-tetrazole derivatives as potential agents against Alzheimer’s disease.Bioorg. Med. Chem. Lett.2019291667210.1016/j.bmcl.2018.11.00530455151
     [Google Scholar]
193. Abd El-KarimS.S. AnwarM.M. AhmedN.S. SyamY.M. ElseginyS.A. AlyH.F. YounisE.A. KhalilW.K.B. AhmedK.A. MohammedF.F. RizkM. Discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease: Design, synthesis, biological evaluation, molecular docking and 3D-QSAR investigation.Eur. J. Med. Chem.202326011576610.1016/j.ejmech.2023.11576637678141
     [Google Scholar]
194. LiX. LiT. ZhangP. LiX. LuL. SunY. ZhangB. AllenS. WhiteL. PhillipsJ. ZhuZ. YaoH. XuJ. Discovery of novel hybrids containing clioquinol−1-benzyl-1,2,3,6-tetrahydropyridine as multi-target-directed ligands (MTDLs) against Alzheimer’s disease.Eur. J. Med. Chem.202224411484110.1016/j.ejmech.2022.11484136257284
     [Google Scholar]
195. ManzoorS. PrajapatiS.K. MajumdarS. RazaM.K. GabrM.T. KumarS. PalK. RashidH. KumarS. KrishnamurthyS. HodaN. Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer’s action: Design, synthesis, crystal structure and in-vitro biological evaluation.Eur. J. Med. Chem.202121511322410.1016/j.ejmech.2021.11322433582578
     [Google Scholar]
196. EstradaM. Herrera-ArozamenaC. PérezC. ViñaD. RomeroA. Morales-GarcíaJ.A. Pérez-CastilloA. Rodríguez-FrancoM.I. New cinnamic – N-benzylpiperidine and cinnamic – N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties.Eur. J. Med. Chem.201612137638610.1016/j.ejmech.2016.05.05527267007
     [Google Scholar]
197. WangJ. CaiP. YangX.L. LiF. WuJ.J. KongL.Y. WangX.B. Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer’s disease.Eur. J. Med. Chem.2017139688310.1016/j.ejmech.2017.07.07728800459
     [Google Scholar]
198. PagoniA. MarinelliL. Di StefanoA. CiullaM. TurkezH. MardinogluA. VassiliouS. CacciatoreI. Novel anti-Alzheimer phenol-lipoyl hybrids: Synthesis, physico-chemical characterization, and biological evaluation.Eur. J. Med. Chem.202018611188010.1016/j.ejmech.2019.11188031753513
     [Google Scholar]
199. XieY. ChenC. LinS. YuX. YeS. ChenX. OuyangN. XiongW. LiC. XuC. SongG. WuH. Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3β.Eur. J. Med. Chem.202324811508910.1016/j.ejmech.2023.11508936638710
     [Google Scholar]
200. BlaikieL. KayG. Kong Thoo LinP. Synthesis and in vitro evaluation of vanillin derivatives as multi-target therapeutics for the treatment of Alzheimer’s disease.Bioorg. Med. Chem. Lett.2020302112750510.1016/j.bmcl.2020.12750532822761
     [Google Scholar]
201. ZhangZ. GuoJ. ChengM. ZhouW. WanY. WangR. FangY. JinY. LiuJ. XieS.S. Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.202121311315410.1016/j.ejmech.2021.11315433476932
     [Google Scholar]
202. AlbuquerqueH.M.T. Nunes da SilvaR. PereiraM. MaiaA. GuieuS. SoaresA.R. SantosC.M.M. VieiraS.I. SilvaA.M.S. Steroid–Quinoline Hybrids for Disruption and Reversion of Protein Aggregation Processes.ACS Med. Chem. Lett.202213344344810.1021/acsmedchemlett.1c0060435300075
     [Google Scholar]
203. WangB. WangZ. ChenH. LuC.J. LiX. Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.Bioorg. Med. Chem.201624194741474910.1016/j.bmc.2016.08.01727567080
     [Google Scholar]
204. LuoZ. LiangL. ShengJ. PangY. LiJ. HuangL. LiX. Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer’s disease.Bioorg. Med. Chem.20142241355136110.1016/j.bmc.2013.12.06624461494
     [Google Scholar]
205. SchulzeM. SiolO. DeckerM. LehmannJ. Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: Novel heterocyclic templates for butyrylcholinesterase inhibitors.Bioorg. Med. Chem. Lett.20102092946294910.1016/j.bmcl.2010.03.01120350808
     [Google Scholar]
206. XuZ.C. WangX.B. YuW.Y. XieS.S. LiS.Y. KongL.Y. Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer’s disease.Bioorg. Med. Chem. Lett.201424102368237310.1016/j.bmcl.2014.03.05824726809
     [Google Scholar]
207. KarabelyovV. Kondeva-BurdinaM. AngelovaV.T. Synthetic approaches to unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles and their MAO-B inhibitory activity. A review.Bioorg. Med. Chem.20212911588810.1016/j.bmc.2020.11588833360082
     [Google Scholar]
208. ZhongZ. HeX. GeJ. ZhuJ. YaoC. CaiH. YeX.Y. XieT. BaiR. Discovery of small-molecule compounds and natural products against Parkinson’s disease: Pathological mechanism and structural modification.Eur. J. Med. Chem.202223711437810.1016/j.ejmech.2022.11437835462165
     [Google Scholar]
209. SashidharaK.V. ModukuriR.K. JadiyaP. RaoK.B. SharmaT. HaqueR. SinghD.K. BanerjeeD. SiddiqiM.I. NazirA. Discovery of 3-arylcoumarin-tetracyclic tacrine hybrids as multifunctional agents against Parkinson’s disease.ACS Med. Chem. Lett.20145101099110310.1021/ml500222g25313319
     [Google Scholar]
210. LüM.H. WangZ.P. XingL.Z. ZhangW. HanF. HuangG.L. LiuW. ZhangY.X. XuJ. CuiJ. Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate α-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice.Eur. J. Med. Chem.202324911512210.1016/j.ejmech.2023.11512236680987
     [Google Scholar]
211. Di MartinoR.M.C. PruccoliL. BisiA. GobbiS. RampaA. MartinezA. PérezC. Martinez-GonzalezL. PaglioneM. Di SchiaviE. SeghettiF. TarozziA. BellutiF. Novel curcumin-diethyl fumarate hybrid as a dualistic GSK-3β inhibitor/Nrf2 Inducer for the treatment of Parkinson’s disease.ACS Chem. Neurosci.202011172728274010.1021/acschemneuro.0c0036332663009
     [Google Scholar]
212. PinnenF. CacciatoreI. CornacchiaC. MollicaA. SozioP. CerasaL.S. IannitelliA. FontanaA. NasutiC. Di StefanoA. CNS delivery of l-dopa by a new hybrid glutathione–methionine peptidomimetic prodrug.Amino Acids201242126126910.1007/s00726‑010‑0804‑z21080012
     [Google Scholar]
213. ShenZ.B. MengH.W. MengX.S. LvZ.K. FangM.Y. ZhangL.L. LvZ.L. LiM.S. LiuA.K. HanJ.H. LiQ.S. DuanY.J. Design, synthesis, and SAR study of novel flavone 1,2,4-oxadiazole derivatives with anti-inflammatory activities for the treatment of Parkinson’s disease.Eur. J. Med. Chem.202325511541710.1016/j.ejmech.2023.11541737137246
     [Google Scholar]
214. GhogareJ.G. BhandariS.V. BotharaK.G. MadgulkarA.R. ParasharG.A. SonawaneB.G. InamdarP.R. Design, synthesis and pharmacological screening of potential anticonvulsant agents using hybrid approach.Eur. J. Med. Chem.201045385786310.1016/j.ejmech.2009.09.01420034707
     [Google Scholar]
215. MarcinkowskaM. MordylB. Fajkis-ZajaczkowskaN. SiwekA. KarczT. GawalskaA. BuckiA. ŻmudzkiP. PartykaA. Jastrzębska-WięsekM. PomiernyB. WalczakM. SmolikM. PytkaK. MikaK. KotańskaM. KolaczkowskiM. Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression.Eur. J. Med. Chem.202324711507110.1016/j.ejmech.2022.11507136603509
     [Google Scholar]
216. MalikS. BahareR.S. KhanS.A. Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: A hybrid pharmacophore approach.Eur. J. Med. Chem.20136711310.1016/j.ejmech.2013.06.02623831504
     [Google Scholar]
217. ZarębaP. SałatK. HöfnerG.C. ŁątkaK. BajdaM. LataczG. KotniewiczK. RapaczA. PodkowaA. MajM. JóźwiakK. FilipekB. WannerK.T. MalawskaB. KuligK. Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.Eur. J. Med. Chem.202122111351210.1016/j.ejmech.2021.11351234015586
     [Google Scholar]
218. YogeeswariP. SriramD. SahityaP. RagavendranJ.V. RanganadhV. Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: A pharmacophoric hybrid approach.Bioorg. Med. Chem. Lett.200717133712371510.1016/j.bmcl.2007.04.03217481896
     [Google Scholar]
219. LiuW. WangH. LiX. XuY. ZhangJ. WangW. GongQ. QiuX. ZhuJ. MaoF. ZhangH. LiJ. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.Bioorg. Med. Chem.201826123117312510.1016/j.bmc.2018.04.03729729987
     [Google Scholar]
220. AbramM. RapaczA. LataczG. SzulczykB. Kalinowska-TłuścikJ. Otto-ŚlusarczykD. StrugaM. KamińskiR.M. KamińskiK. Asymmetric synthesis and in vivo/in vitro characterization of new hybrid anticonvulsants derived from (2,5-dioxopyrrolidin-1-yl)phenylacetamides.Bioorg. Chem.202110910475110.1016/j.bioorg.2021.10475133647745
     [Google Scholar]
221. KamińskiK. ZagajaM. RapaczA. ŁuszczkiJ.J. Andres-MachM. AbramM. ObniskaJ. New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.Bioorg. Med. Chem.201624460661810.1016/j.bmc.2015.12.02726746343
     [Google Scholar]
222. SunX. LiN. ZhongP. ChenL. SunJ. Development of MAO-A and 5-HT2AR dual Inhibitors with Improved antidepressant activity.J. Med. Chem.20226519133851340010.1021/acs.jmedchem.2c0127136173886
     [Google Scholar]
223. SashidharaK.V. RaoK.B. SinghS. ModukuriR.K. Aruna TejaG. ChandasanaH. ShuklaS. BhattaR.S. Synthesis and evaluation of new 3-phenylcoumarin derivatives as potential antidepressant agents.Bioorg. Med. Chem. Lett.201424204876488010.1016/j.bmcl.2014.08.03725239852
     [Google Scholar]
224. SashidharaK.V. ModukuriR.K. SinghS. Bhaskara RaoK. Aruna TejaG. GuptaS. ShuklaS. Design and synthesis of new series of coumarin–aminopyran derivatives possessing potential anti-depressant-like activity.Bioorg. Med. Chem. Lett.201525233734110.1016/j.bmcl.2014.11.03625488839
     [Google Scholar]
225. ZhouJ. KläßT. JohnsonK.M. GibersonK.M. KozikowskiA.P. Discovery of novel conformationally constrained tropane-based biaryl and arylacetylene ligands as potent and selective norepinephrine transporter inhibitors and potential antidepressants.Bioorg. Med. Chem. Lett.200515102461246510.1016/j.bmcl.2005.03.08315863297
     [Google Scholar]
226. HuangZ.H. YinL.Q. GuanL.P. LiZ.H. TanC. Screening of chalcone analogs with anti-depressant, anti-inflammatory, analgesic, and COX-2-inhibiting effects.Bioorg. Med. Chem. Lett.2020301112717310.1016/j.bmcl.2020.12717332278513
     [Google Scholar]
227. DuY. GaoF. SunH. WuC. ZhuG. ZhuM. Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice.Eur. J. Med. Chem.202326111585510.1016/j.ejmech.2023.11585537847955
     [Google Scholar]
228. Dalton KingH. DenhartD.J. DeskusJ.A. DittaJ.L. EppersonJ.R. HigginsM.A. KungJ.E. MarcinL.R. SloanC.P. MattsonG.K. MolskiT.F. KrauseR.G. BertekapR.L.Jr LodgeN.J. MattsonR.J. MacorJ.E. Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.Bioorg. Med. Chem. Lett.200717205647565110.1016/j.bmcl.2007.07.08317766113
     [Google Scholar]
229. Abdul-HayS. SchieferI.T. ChandrasenaR.E.P. LiM. AbdelhamidR. WangY.T. TavassoliE. MichalsenB. AsghodomR.T. LuoJ. ThatcherG.R.J. NO-SSRIs: Nitric oxide chimera drugs incorporating a selective serotonin reuptake inhibitor.ACS Med. Chem. Lett.20112965666110.1021/ml200003321927645
     [Google Scholar]
230. MedinaR.A. Vázquez-VillaH. Gómez-TamayoJ.C. BenhamúB. Martín-FontechaM. de la FuenteT. CaltabianoG. HedlundP.B. PardoL. López-RodríguezM.L. The extracellular entrance provides selectivity to serotonin 5-HT7 receptor antagonists with antidepressant-like behavior in vivo. J. Med. Chem.201457156879688410.1021/jm500880c25073094
     [Google Scholar]
231. MohsinN.A. AhmadM. Hybrid organic molecules as antiinflammatory agents; a review of structural features and biological activity.Turk. J. Chem.20184212010.3906/kim‑1706‑58
     [Google Scholar]
232. ChenT. ZhuG. MengX. ZhangX. Recent developments of small molecules with anti-inflammatory activities for the treatment of acute lung injury.Eur. J. Med. Chem.202020711266010.1016/j.ejmech.2020.11266032916382
     [Google Scholar]
233. PereiraR. SilvaA.M.S. RibeiroD. SilvaV.L.M. FernandesE. Bis-chalcones: A review of synthetic methodologies and anti-inflammatory effects.Eur. J. Med. Chem.202325211528010.1016/j.ejmech.2023.11528036966653
     [Google Scholar]
234. GascoA. BoschiD. ChegaevK. CenaC. Di StiloA. FrutteroR. LazzaratoL. RolandoB. ToscoP. Multitarget drugs: Focus on the NO-donor hybrid drugs.Pure Appl. Chem.20088081693170110.1351/pac200880081693
     [Google Scholar]
235. MartelliA. RapposelliS. CalderoneV. NO-releasing hybrids of cardiovascular drugs.Curr. Med. Chem.200613660962510.2174/09298670677605563416529554
     [Google Scholar]
236. MartelliA. BreschiM. CalderoneV. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties.Curr. Pharm. Des.200915661463610.2174/13816120978731561119199986
     [Google Scholar]
237. SerafimR.A.M. PrimiM.C. TrossiniG.H.G. FerreiraE.I. Nitric oxide: state of the art in drug design.Curr. Med. Chem.201219338640510.2174/09298671280341432122335514
     [Google Scholar]
238. BhardwajA. KaurJ. KnausE.E. Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?Future Med. Chem.20135438138310.4155/fmc.13.2323495685
     [Google Scholar]
239. AbdelallE.K.A. AbdelhamidA.O. AzouzA.A. Synthesis and biological evaluations of new nitric oxide-anti-inflammatory drug hybrids.Bioorg. Med. Chem. Lett.201727184358436910.1016/j.bmcl.2017.08.02328844389
     [Google Scholar]
240. MontanaroG. BertinariaM. RolandoB. FrutteroR. LucasC.D. DorwardD.A. RossiA.G. MegsonI.L. GascoA. Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents.Bioorg. Med. Chem.20132172107211610.1016/j.bmc.2013.01.00923394865
     [Google Scholar]
241. KodelaR. ChattopadhyayM. KashfiK. NOSH-Aspirin: A novel nitric oxide-hydrogen sulfide-releasing hybrid: A new class of anti-inflammatory pharmaceuticals.ACS Med. Chem. Lett.20123325726210.1021/ml300002m22916316
     [Google Scholar]
242. AbadiA.H. HegazyG.H. El-ZaherA.A. Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and anti-inflammatory agents.Bioorg. Med. Chem.200513205759576510.1016/j.bmc.2005.05.05316002298
     [Google Scholar]
243. ChandakS.L. BansodeA.S. MurumkarP.R. ShindeM.G. BotharaK.G. Synthesis and investigation of anti-inflammatory activity of novel nitric oxide donating hybrid drugs.Med. Chem. Res.20132273510351710.1007/s00044‑012‑0345‑y
     [Google Scholar]
244. VelázquezC. RaoP.N.P. McDonaldR. KnausE.E. Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents.Bioorg. Med. Chem.20051382749275710.1016/j.bmc.2005.02.03415781386
     [Google Scholar]
245. HernándezP. CabreraM. LavaggiM.L. CelanoL. TiscorniaI. Rodrigues da CostaT. ThomsonL. Bollati-FogolínM. MirandaA.L.P. LimaL.M. BarreiroE.J. GonzálezM. CerecettoH. Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives.Bioorg. Med. Chem.20122062158217110.1016/j.bmc.2012.01.03422356737
     [Google Scholar]
246. VelázquezC.A. Praveen RaoP.N. CitroM.L. KeeferL.K. KnausE.E. O2-Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO–NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies.Bioorg. Med. Chem.200715144767477410.1016/j.bmc.2007.05.00917509888
     [Google Scholar]
247. AbdellatifK.R.A. ChowdhuryM.A. DongY. ChenQ.H. KnausE.E. Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: Synthesis, cyclooxygenase inhibition, and nitric oxide release studies.Bioorg. Med. Chem.20081663302330810.1016/j.bmc.2007.12.00618096394
     [Google Scholar]
248. AbdellatifK.R.A. ChowdhuryM.A. DongY. VelázquezC. DasD. SureshM.R. KnausE.E. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.Bioorg. Med. Chem.200816229694969810.1016/j.bmc.2008.10.00118930406
     [Google Scholar]
249. AbdellatifK.R.A. ChowdhuryM.A. DongY. DasD. YuG. VelázquezC. SureshM.R. KnausE.E. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.Bioorg. Med. Chem.200917145182518810.1016/j.bmc.2009.05.04619500994
     [Google Scholar]
250. AbdellatifK.R.A. ChowdhuryM.A. DongY. DasD. YuG. VelázquezC.A. SureshM.R. KnausE.E. Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies.Bioorg. Med. Chem. Lett.200919113014301810.1016/j.bmcl.2009.04.05919419861
     [Google Scholar]
251. Abdel-HafezE.S.M.N. Abuo-RahmaG.E.D.A.A. Abdel-AzizM. RadwanM.F. FaragH.H. Design, synthesis and biological investigation of certain pyrazole-3-carboxylic acid derivatives as novel carriers for nitric oxide.Bioorg. Med. Chem.200917113829383710.1016/j.bmc.2009.04.03719419878
     [Google Scholar]
252. Abdel-AzizM. Abuo-RahmaG.E.D.A.A. BeshrE.A.M. AliT.F.S. New nitric oxide donating 1,2,4-triazole/oxime hybrids: Synthesis, investigation of anti-inflammatory, ulceroginic liability and antiproliferative activities.Bioorg. Med. Chem.201321133839384910.1016/j.bmc.2013.04.02223665142
     [Google Scholar]
253. BiW. BiY. GaoX. YanX. ZhangY. XueP. BammertC.E. LegalleyT.D. Michael GibsonK. BiL. WangJ.X. Anti-inflammatory, analgesic and antioxidant activities of novel kyotorphin-nitroxide hybrid molecules.Bioorg. Med. Chem. Lett.20162682005201310.1016/j.bmcl.2016.02.08626961795
     [Google Scholar]
254. LiY.R. LiC. LiuJ.C. GuoM. ZhangT.Y. SunL.P. ZhengC.J. PiaoH.R. Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.Bioorg. Med. Chem. Lett.201525225052505710.1016/j.bmcl.2015.10.02826490095
     [Google Scholar]
255. KaurG. SilakariO. Benzimidazole scaffold based hybrid molecules for various inflammatory targets: Synthesis and evaluation.Bioorg. Chem.201880243510.1016/j.bioorg.2018.05.01429864685
     [Google Scholar]
256. GhanimA.M. RezqS. IbrahimT.S. RomeroD.G. KothayerH. Novel 1,2,4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition.Eur. J. Med. Chem.202121911345710.1016/j.ejmech.2021.11345733892270
     [Google Scholar]
257. RadwanM.F. DalbyK.N. KaoudT.S. Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.ACS Med. Chem. Lett.20145998398810.1021/ml500156v25221653
     [Google Scholar]
258. MaghrabyM.T.E. Abou-GhadirO.M.F. Abdel-MotyS.G. AliA.Y. SalemO.I.A. Novel class of benzimidazole-thiazole hybrids: The privileged scaffolds of potent anti-inflammatory activity with dual inhibition of cyclooxygenase and 15-lipoxygenase enzymes.Bioorg. Med. Chem.202028711540310.1016/j.bmc.2020.11540332127262
     [Google Scholar]
259. SinhaS. ManjuS.L. DobleM. Chalcone-thiazole hybrids: rational design, synthesis, and lead identification against 5-lipoxygenase.ACS Med. Chem. Lett.201910101415142210.1021/acsmedchemlett.9b0019331620227
     [Google Scholar]
260. AbdelazeemA.H. Safi El-DinA.G. Abdel-FattahM.M. AminN.H. El-MoghazyS.M. El-SaadiM.T. Discovery of novel urea-diarylpyrazole hybrids as dual COX-2/sEH inhibitors with improved anti-inflammatory activity and highly reduced cardiovascular risks.Eur. J. Med. Chem.202020511266210.1016/j.ejmech.2020.11266232763463
     [Google Scholar]
261. MartelliA. TestaiL. AnziniM. CappelliA. Di CapuaA. BiavaM. PoceG. ConsalviS. GiordaniA. CaselliG. RovatiL. GhelardiniC. PatrignaniP. SautebinL. BreschiM.C. CalderoneV. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.Pharmacol. Res.2013781910.1016/j.phrs.2013.09.00824083950
     [Google Scholar]
262. ChowdhuryM.A. AbdellatifK.R.A. DongY. DasD. SureshM.R. KnausE.E. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: Biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.Bioorg. Med. Chem. Lett.200818236138614110.1016/j.bmcl.2008.10.00918945614
     [Google Scholar]
263. FuZ.Y. JinQ.H. QuY.L. GuanL.P. Chalcone derivatives bearing chromen or benzo[f]chromen moieties: Design, synthesis, and evaluations of anti-inflammatory, analgesic, selective COX-2 inhibitory activities.Bioorg. Med. Chem. Lett.201929151909191210.1016/j.bmcl.2019.05.05131160177
     [Google Scholar]
264. AbbasS.E. AwadallahF.M. IbrahinN.A. SaidE.G. KamelG.M. New quinazolinone–pyrimidine hybrids: Synthesis, anti-inflammatory, and ulcerogenicity studies.Eur. J. Med. Chem.20125314114910.1016/j.ejmech.2012.03.05022551678
     [Google Scholar]
265. BiavaM. BattilocchioC. PoceG. AlfonsoS. ConsalviS. PorrettaG.C. SchenoneS. CalderoneV. MartelliA. TestaiL. GhelardiniC. Di Cesare MannelliL. SautebinL. RossiA. GiordaniA. PatrignaniP. AnziniM. Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme.Eur. J. Med. Chem.20125828729810.1016/j.ejmech.2012.10.01423131542
     [Google Scholar]
266. AlsafiM.H.A. FarhanM.S. Synthesis, characterization and acute anti-inflammatory evaluation of new mefenamic acid derivatives having 4-thiazolidinone nucleus.Iraqi J. Pharm Sci.20192813814610.31351/vol28iss1pp138‑146
     [Google Scholar]
267. KashidB.B. SalunkheP.H. DongareB.B. MoreK.R. KhedkarV.M. GhanwatA.A. Synthesis of novel of 2, 5-disubstituted 1, 3, 4- oxadiazole derivatives and their in vitro anti-inflammatory, anti-oxidant evaluation, and molecular docking study.Bioorg. Med. Chem. Lett.2020301212713610.1016/j.bmcl.2020.12713632280025
     [Google Scholar]
268. PanJ. XuT. XuF. ZhangY. LiuZ. ChenW. FuW. DaiY. ZhaoY. FengJ. LiangG. Development of resveratrol-curcumin hybrids as potential therapeutic agents for inflammatory lung diseases.Eur. J. Med. Chem.201712547849110.1016/j.ejmech.2016.09.03327689730
     [Google Scholar]
269. KumarR.S. AntonisamyP. AlmansourA.I. ArumugamN. PeriyasamiG. AltafM. KimH.R. KwonK.B. Functionalized spirooxindole-indolizine hybrids: Stereoselective green synthesis and evaluation of anti-inflammatory effect involving TNF-α and nitrite inhibition.Eur. J. Med. Chem.201815241742310.1016/j.ejmech.2018.04.06029751235
     [Google Scholar]
270. HatnapureG.D. KecheA.P. RodgeA.H. BirajdarS.S. TaleR.H. KambleV.M. Synthesis and biological evaluation of novel piperazine derivatives of flavone as potent anti-inflammatory and antimicrobial agent.Bioorg. Med. Chem. Lett.201222206385639010.1016/j.bmcl.2012.08.07122981334
     [Google Scholar]
271. MachadoA.L. LimaL.M. Araújo-J.X.Jr FragaC.A.M. Gonçalves KoatzV.L. BarreiroE.J. Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide.Bioorg. Med. Chem. Lett.20051541169117210.1016/j.bmcl.2004.12.01215686935
     [Google Scholar]
272. ZhangZ. CaoP. FangM. ZouT. HanJ. DuanY. XuH. YangX. LiQ.S. Design, synthesis, and SAR study of novel 4,5-dihydropyrazole-Thiazole derivatives with anti-inflammatory activities for the treatment of sepsis.Eur. J. Med. Chem.202122511374310.1016/j.ejmech.2021.11374334403978
     [Google Scholar]
273. KatoT. FukaoK. OharaT. NayaN. TokuyamaR. MutoS. FukasawaH. ItaiA. MatsumuraK. Design, synthesis, and anti-inflammatory evaluation of a novel PPARδ agonist with a 4-(1-pyrrolidinyl)piperidine structure.J. Med. Chem.20236616114281144610.1021/acs.jmedchem.3c0093237552807
     [Google Scholar]
274. LimaL.M. CastroP. MachadoA.L. FragaC.A.M. LugnierC. de MoraesV.L.G. BarreiroE.J. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues.Bioorg. Med. Chem.20021093067307310.1016/S0968‑0896(02)00152‑912110331
     [Google Scholar]
275. LamieP. PhiloppesJ. El-GendyA. RarovaL. GruzJ. Design, synthesis and evaluation of novel phthalimide derivatives as antimicrobial, antioxidant and anti-inflammatory agents.Molecules2015209166201664210.3390/molecules20091662026389864
     [Google Scholar]
276. LacerdaR.B. de LimaC.K.F. da SilvaL.L. RomeiroN.C. MirandaA.L.P. BarreiroE.J. FragaC.A.M. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.Bioorg. Med. Chem.2009171748410.1016/j.bmc.2008.11.01819059783
     [Google Scholar]
277. BerrinoE. MicheliL. CarradoriS. di Cesare MannelliL. GuglielmiP. De LucaA. CartaF. GhelardiniC. SecciD. SupuranC.T. Novel Insights on CAI−CORM hybrids: Evaluation of the CO releasing properties and pain-relieving activity of differently substituted coumarins for the treatment of rheumatoid arthritis.J. Med. Chem.20236631892190810.1021/acs.jmedchem.2c0170636701258
     [Google Scholar]
278. Hadjipavlou-LitinaD. MagoulasG.E. BariamisS.E. DrainasD. AvgoustakisK. PapaioannouD. Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?Bioorg. Med. Chem.201018238204821710.1016/j.bmc.2010.10.01221041094
     [Google Scholar]
279. ChenW. GeX. XuF. ZhangY. LiuZ. PanJ. SongJ. DaiY. ZhouJ. FengJ. LiangG. Design, synthesis and biological evaluation of paralleled Aza resveratrol–chalcone compounds as potential anti-inflammatory agents for the treatment of acute lung injury.Bioorg. Med. Chem. Lett.201525152998300410.1016/j.bmcl.2015.05.03026048788
     [Google Scholar]
280. AldawsariF.S. AguiarR.P. WiirzlerL.A.M. Aguayo-OrtizR. AljuhaniN. CumanR.K.N. Medina-FrancoJ.L. SirakiA.G. Velázquez-MartínezC.A. Anti-inflammatory and antioxidant properties of a novel resveratrol–salicylate hybrid analog.Bioorg. Med. Chem. Lett.20162651411141510.1016/j.bmcl.2016.01.06926850006
     [Google Scholar]
281. ZhengX.J. LiC.S. CuiM.Y. SongZ.W. BaiX.Q. LiangC.W. WangH.Y. ZhangT.Y. Synthesis, biological evaluation of benzothiazole derivatives bearing a 1,3,4-oxadiazole moiety as potential and anti-inflammatory agents.Bioorg. Med. Chem. Lett.20203012723710.1016/j.bmcl.2020.127237
     [Google Scholar]
282. ZhengX.J. LiC.S. CuiM.Y. SongZ.W. BaiX.Q. LiangC.W. WangH.Y. ZhangT.Y. Synthesis, biological evaluation of benzothiazole derivatives bearing a 1,3,4-oxadiazole moiety as potential anti-oxidant and anti-inflammatory agents.Bioorg. Med. Chem. Lett.2020301312723710.1016/j.bmcl.2020.12723732386981
     [Google Scholar]
283. KankalaS. KankalaR.K. GundepakaP. ThotaN. NerellaS. GangulaM.R. GugulothH. KaggaM. VaddeR. VasamC.S. Regioselective synthesis of isoxazole–mercaptobenzimidazole hybrids and their in vivo analgesic and anti-inflammatory activity studies.Bioorg. Med. Chem. Lett.20132351306130910.1016/j.bmcl.2012.12.10123357631
     [Google Scholar]
284. MengheresG. RiceC.R. OlajideO.A. HemmingK. Synthesis of novel isoflavone/benzo-δ-sultam hybrids as potential anti-inflammatory drugs.Bioorg. Med. Chem. Lett.20213412776110.1016/j.bmcl.2020.12776133359607
     [Google Scholar]
285. HuangS.T. LiaoJ.S. FangH.W. LinC.M. Synthesis and anti-inflammation evaluation of new C60 fulleropyrrolidines bearing biologically active xanthine.Bioorg. Med. Chem. Lett.20081819910310.1016/j.bmcl.2007.11.00418023183
     [Google Scholar]
286. LuoX. XiongH. JiangY. FanY. ZuoC. ChenD. ChenL. LinH. GaoJ. Macrophage reprogramming via targeted ROS scavenging and COX-2 downregulation for alleviating inflammation.Bioconjug. Chem.20233471316132610.1021/acs.bioconjchem.3c0023937330989
     [Google Scholar]
287. WangW. WangS.K. WangQ. ZhangZ. LiB. ZhouZ.D. ZhangJ.F. LinC. ChenT.X. JinZ. TangY.Z. Diclofenac and eugenol hybrid with enhanced anti-inflammatory activity through activating HO-1 and inhibiting NF-κB pathway in vitro and in vivo. Eur. J. Med. Chem.202325911566910.1016/j.ejmech.2023.11566937517204
     [Google Scholar]
288. AkhtarM. NiuJ. ZhuY. LuoZ. TianT. DongY. WangY. FareedM.S. LinL. Anti-inflammatory efficacy and relevant SAR investigations of novel chiral pyrazolo isoquinoline derivatives: Design, synthesis, in-vitro, in-vivo, and computational studies targeting iNOS.Eur. J. Med. Chem.202325611541210.1016/j.ejmech.2023.11541237146344
     [Google Scholar]
289. LiS.M. ChouJ.Y. TsaiS.E. TsengC.C. ChungC.Y. ZengW.Z. HuY.P. UramaruN. HuangG.J. WongF.F. Synthesis and anti-inflammatory activity evaluation of NO-releasing furoxan/1,2,4-triazole hybrid derivatives.Eur. J. Med. Chem.202325711549610.1016/j.ejmech.2023.11549637224762
     [Google Scholar]
290. LiX. HuY. HeB. LiL. TianY. XiaoY. ShangH. ZouZ. Design, synthesis and evaluation of ursodeoxycholic acid-cinnamic acid hybrids as potential anti-inflammatory agents by inhibiting Akt/NF-κB and MAPK signaling pathways.Eur. J. Med. Chem.202326011578510.1016/j.ejmech.2023.11578537678142
     [Google Scholar]
291. AuvinS. AuguetM. NavetE. HarnettJ.J. ViossatI. SchulzJ. BiggD. ChabrierP.E. Novel inhibitors of neuronal nitric oxide synthase with potent antioxidant properties.Bioorg. Med. Chem. Lett.200313220921210.1016/S0960‑894X(02)00883‑112482425
     [Google Scholar]
292. Vázquez-JiménezL. GarridoM. MiceliM. PratsE. Ferrer-MontielA. TeixidóM. JimenoC. MesseguerA. Synthesis and in vitro, ex-vivo and in vivo activity of hybrid compounds linking a potent ROS and RNS scavenger activity with diverse substrates addressed to pass across the blood-brain barrier.Eur. J. Med. Chem.201612378880210.1016/j.ejmech.2016.08.00727541262
     [Google Scholar]
293. YooY.J. NamD.H. JungS.Y. JangJ.W. KimH.J. JinC. PaeA.N. LeeY.S. Synthesis of cinnamoyl ketoamides as hybrid structures of antioxidants and calpain inhibitors.Bioorg. Med. Chem. Lett.201121102850285410.1016/j.bmcl.2011.03.07721504847
     [Google Scholar]
294. SahuP.K. Design, structure activity relationship, cytotoxicity and evaluation of antioxidant activity of curcumin derivatives/analogues.Eur. J. Med. Chem.201612151051610.1016/j.ejmech.2016.05.03727318975
     [Google Scholar]
295. SahuP.K. SahuP.K. SahuP.L. AgarwalD.D. Structure activity relationship, cytotoxicity and evaluation of antioxidant activity of curcumin derivatives.Bioorg. Med. Chem. Lett.20162641342134710.1016/j.bmcl.2015.12.01326810315
     [Google Scholar]
296. MatosM. MuraF. Vazquez-RodriguezS. BorgesF. SantanaL. UriarteE. Olea-AzarC. Study of coumarin-resveratrol hybrids as potent antioxidant compounds.Molecules20152023290330810.3390/molecules2002329025690290
     [Google Scholar]
297. BuendiaI. NavarroE. MichalskaP. GameiroI. EgeaJ. AbrilS. LópezA. González-LafuenteL. LópezM.G. LeónR. New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection.Future Med. Chem.20157151961196910.4155/fmc.15.9926496465
     [Google Scholar]
298. DurandG. PolidoriA. SallesJ.P. ProstM. DurandP. PucciB. Synthesis and antioxidant efficiency of a new amphiphilic spin-trap derived from PBN and lipoic acid.Bioorg. Med. Chem. Lett.200313162673267610.1016/S0960‑894X(03)00545‑612873491
     [Google Scholar]
299. DowarahJ. SinghV.P. Anti-diabetic drugs recent approaches and advancements.Bioorg. Med. Chem.202028511526310.1016/j.bmc.2019.11526332008883
     [Google Scholar]
300. LiuC. MiaoR. RazaF. QianH. TianX. Research progress and challenges of TRPV1 channel modulators as a prospective therapy for diabetic neuropathic pain.Eur. J. Med. Chem.2023245Pt 111489310.1016/j.ejmech.2022.11489336395649
     [Google Scholar]
301. IbrahimM.K. EissaI.H. AlesawyM.S. MetwalyA.M. RadwanM.M. ElSohlyM.A. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.Bioorg. Med. Chem.201725174723474410.1016/j.bmc.2017.07.01528720328
     [Google Scholar]
302. SatishS. SrivastavaA. YadavP. VarshneyS. ChoudharyR. BalaramnavarV.M. NarenderT. GaikwadA.N. Aegeline inspired synthesis of novel amino alcohol and thiazolidinedione hybrids with antiadipogenic activity in 3T3-L1 cells.Eur. J. Med. Chem.201814378079110.1016/j.ejmech.2017.11.04129220798
     [Google Scholar]
303. HuangF. ZengZ. ZhangW. YanZ. ChenJ. YuL. YangQ. LiY. YuH. ChenJ. WuC. ZhangX. SuY. ZhouH. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.Eur. J. Med. Chem.202122211354210.1016/j.ejmech.2021.11354234118723
     [Google Scholar]
304. RajanS. PuriS. KumarD. BabuM.H. ShankarK. VarshneyS. SrivastavaA. GuptaA. ReddyM.S. GaikwadA.N. Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.Eur. J. Med. Chem.20181431345136010.1016/j.ejmech.2017.10.03429153558
     [Google Scholar]
305. KinfeH.H. BelayY.H. JosephJ.S. MukwevhoE. Evaluation of the Influence of thiosemicarbazone–triazole hybrids on genes implicated in lipid oxidation and accumulation as potential anti-obesity agents.Bioorg. Med. Chem. Lett.201323195275527810.1016/j.bmcl.2013.08.02823988353
     [Google Scholar]
306. XiaoD. LuL. LiangB. XiongZ. XuX. ChenW.H. Identification of 1,3,4-oxadiazolyl-containing β-carboline derivatives as novel α-glucosidase inhibitors with antidiabetic activity.Eur. J. Med. Chem.202326111579510.1016/j.ejmech.2023.11579537688939
     [Google Scholar]
307. ShahM. JanM.S. SadiqA. KhanS. RashidU. SAR and lead optimization of (Z)-5-(4-hydroxy-3-methoxybenzylidene)-3-(2-morpholinoacetyl)thiazolidine-2,4-dione as a potential multi-target antidiabetic agent.Eur. J. Med. Chem.202325811559110.1016/j.ejmech.2023.11559137393789
     [Google Scholar]
308. MushtaqA. AzamU. MehreenS. NaseerM.M. Synthetic α-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges.Eur. J. Med. Chem.202324911511910.1016/j.ejmech.2023.11511936680985
     [Google Scholar]
309. CalderoneV. RapposelliS. MartelliA. DigiacomoM. TestaiL. TorriS. MarchettiP. BreschiM.C. BalsamoA. NO-glibenclamide derivatives: Prototypes of a new class of nitric oxide-releasing anti-diabetic drugs.Bioorg. Med. Chem.200917155426543210.1016/j.bmc.2009.06.04919595600
     [Google Scholar]
310. DigiacomoM. MartelliA. TestaiL. LapucciA. BreschiM.C. CalderoneV. RapposelliS. Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications.Bioorg. Med. Chem.201523342242810.1016/j.bmc.2014.12.04325577707
     [Google Scholar]
311. XieY.D. LiuJ.P. WangW. ShiY.H. WangX.P. SunM. XuX.Y. LiN. 3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.Bioorg. Med. Chem. Lett.2020301512727710.1016/j.bmcl.2020.12727732527456
     [Google Scholar]
312. LiZ. XuX. DengL. LiaoR. LiangR. ZhangB. ZhangL. Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.Bioorg. Med. Chem.201826143947395210.1016/j.bmc.2018.06.01729954682
     [Google Scholar]
313. LiZ. XuX. LiuR. DengF. ZengX. ZhangL. Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents.Bioorg. Med. Chem.201826154560456610.1016/j.bmc.2018.07.05030082106
     [Google Scholar]
314. YangQ. ZhouF. TangX. WangJ. FengH. JiangW. JinL. JiangN. YuanY. HanJ. YanZ. Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.Eur. J. Med. Chem.202223311421410.1016/j.ejmech.2022.11421435231829
     [Google Scholar]
315. InoueT. MoritaM. TojoT. YoshiharaK. NagashimaA. MoritomoA. OhkuboM. MiyakeH. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema.Bioorg. Med. Chem.20132151219123310.1016/j.bmc.2012.12.02523337801
     [Google Scholar]
316. ShahK. PatelD. JadavP. SheikhM. SairamK.V.V.M. JoharapurkarA. JainM.R. BahekarR. Discovery of liver selective non-steroidal glucocorticoid receptor antagonist as novel antidiabetic agents.Bioorg. Med. Chem. Lett.201222185857586210.1016/j.bmcl.2012.07.07822917520
     [Google Scholar]
317. ChaidamS. SaehlimN. AthipornchaiA. SirionU. SaeengR. Synthesis and biological evaluation of 1,6-bis-triazole-2,3,4-tri-O-benzyl-α-d-glucopyranosides as a novel α-glucosidase inhibitor in the treatment of Type 2 diabetes.Bioorg. Med. Chem. Lett.20215012833110.1016/j.bmcl.2021.12833134418573
     [Google Scholar]
318. ShengR. YangL. ZhangY. XingE. ShiR. WenX. WangH. SunH. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.Bioorg. Med. Chem. Lett.201828152599260410.1016/j.bmcl.2018.06.04729980358
     [Google Scholar]
319. Hernández-VázquezE. Salgado-BarreraS. Ramírez-EspinosaJ.J. Estrada-SotoS. Hernández-LuisF. SAR and lead optimization of (z)-5-(4-hydroxy-3-methoxybenzylidene)-3-(2-morpholinoacetyl) thiazolidine-2,4-dione as a potential multi-target antidiabetic agent.Bioorg. Med. Chem.2016242298230610.1016/j.bmc.2016.04.00727079123
     [Google Scholar]
320. Hernández-VázquezE. Castañeda-ArriagaR. Ramírez-EspinosaJ.J. Medina-CamposO.N. Hernández-LuisF. ChaverriJ.P. Estrada-SotoS. 1,5-Diarylpyrazole and vanillin hybrids: Synthesis, biological activity and DFT studies.Eur. J. Med. Chem.201510010611810.1016/j.ejmech.2015.06.01026079087
     [Google Scholar]
321. ShuklaP. SinghA.B. SrivastavaA.K. PratapR. Chalcone based aryloxypropanolamines as potential antihyperglycemic agents.Bioorg. Med. Chem. Lett.200717379980210.1016/j.bmcl.2006.10.06817095211
     [Google Scholar]
322. MonteroA. GoyaP. JagerovicN. CalladoL.F. MeanaJ.J. GirónR. GoicoecheaC. MartínM.I. Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for μ opioid and I2-imidazoline receptors: Synthesis and pharmacological screening.Bioorg. Med. Chem.20021041009101810.1016/S0968‑0896(01)00356‑X11836109
     [Google Scholar]
323. DardonvilleC. JagerovicN. CalladoL.F. MeanaJ.J. Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for μ-opioid receptors and I2-imidazoline binding sites.Bioorg. Med. Chem. Lett.200414249149310.1016/j.bmcl.2003.10.04814698188
     [Google Scholar]
324. Romero-HernándezL.L. Merino-MontielP. Montiel-SmithS. Meza-ReyesS. Vega-BáezJ.L. AbasoloI. SchwartzS. LópezÓ. Fernández-BolañosJ.G. Diosgenin-based thio(seleno)ureas and triazolyl glycoconjugates as hybrid drugs. Antioxidant and antiproliferative profile.Eur. J. Med. Chem.201599678110.1016/j.ejmech.2015.05.01826046314
     [Google Scholar]
325. HuangY. HuangW. YangG. WangR. MaL. Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents.Bioorg. Med. Chem. Lett.20214312809210.1016/j.bmcl.2021.12809233964436
     [Google Scholar]
326. ZhouL.C. LiangY.F. HuangY. YangG.X. ZhengL.L. SunJ.M. LiY. ZhuF.L. QianH.W. WangR. MaL. Design, synthesis, and biological evaluation of diosgenin-indole derivatives as dual-functional agents for the treatment of Alzheimer’s disease.Eur. J. Med. Chem.202121911342610.1016/j.ejmech.2021.11342633848787
     [Google Scholar]
327. WangW. WangW. YaoG. RenQ. WangD. WangZ. LiuP. GaoP. ZhangY. WangS. SongS. Novel sarsasapogenin-triazolyl hybrids as potential anti-Alzheimer’s agents: Design, synthesis and biological evaluation.Eur. J. Med. Chem.201815135136210.1016/j.ejmech.2018.03.08229635167
     [Google Scholar]
328. NarenderT. MadhurG. JaiswalN. AgrawalM. MauryaC.K. RahujaN. SrivastavaA.K. TamrakarA.K. Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors.Eur. J. Med. Chem.20136316216910.1016/j.ejmech.2013.01.05323474902
     [Google Scholar]